Predictive Oncology Inc. (NASDAQ:POAI) Short Interest Down 22.7% in March

Predictive Oncology Inc. (NASDAQ:POAI) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 395,800 shares, a decline of 22.7% from the February 28th total of 512,300 shares. Based on an average trading volume of 4,350,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.6% of the shares of the company are short sold.

Predictive Oncology Stock Down 2.6 %

Shares of NASDAQ POAI traded down $0.04 during midday trading on Tuesday, reaching $1.48. 509,511 shares of the stock were exchanged, compared to its average volume of 2,321,013. The firm has a 50-day simple moving average of $1.38 and a two-hundred day simple moving average of $1.03. Predictive Oncology has a twelve month low of $0.55 and a twelve month high of $3.06. The firm has a market cap of $10.13 million, a price-to-earnings ratio of -0.49 and a beta of 1.22.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.